{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:56:11Z","timestamp":1780084571638,"version":"3.54.0"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The effect of adding local ablative radiotherapy on oligo\u2010progression while continuing EGFR\u2010TKIs in advanced non\u2013small cell Lung cancer (NSCLC) patients is to be determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Outcomes of patients with stage IV NSCLC harboring EGFR\u2010activating mutations having\u00a0\u22645 sites of oligo\u2010progression while on EGFR\u2010TKIs and given one to eight fractions of local ablative radiotherapy (LAR) were reviewed from 2012 to 2019. The time of starting first\u2010line EGFR\u2010TKIs to LAR is defined as progression\u2010free survival 1 (PFS1; &gt;\u00a0one line of prior treatment allowed). The primary endpoint was PFS from LAR to further progression that led to stop of EGFR\u2010TKIs (PFS2). The secondary endpoint was overall survival from LAR (OS). Factors affecting PFS2 and OS were analyzed with Cox regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were total 55 eligible patients. The median follow\u2010up time was 13.3 months. Majority (89%) had sensitive mutations (exon 19 deletion and exon 21 L858R mutation). Total number of lesions treated were 75, including lung (<jats:italic>n<\/jats:italic>\u00a0=\u00a045), bone (<jats:italic>n<\/jats:italic>\u00a0=\u00a015), cervical lymph node (<jats:italic>n<\/jats:italic>\u00a0=\u00a01), adrenal (<jats:italic>n<\/jats:italic>\u00a0=\u00a01), and brain (<jats:italic>n<\/jats:italic>\u00a0=\u00a013). The median PFS2 was 6.9 months. The median OS was 25.1 months. On multivariable analysis, it was found that EGFR mutation type (exon 19 deletion \/ exon 21 L858R mutation vs. other rarer mutations), time from diagnosis to LAR within 70 days, and fewer lines of prior TKIs (1 or 2\u00a0vs. 3) had favorable effect on PFS2 (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.006\/0.00003; 0.046; 0.001\/0.005, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LAR is a noninvasive and effective modality in treatment of oligo\u2010progressive diseases for patients with EGFR mutations positive NSCLC while on EGFR\u2010TKIs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13707","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T04:28:58Z","timestamp":1643603338000},"page":"614-624","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Local ablative radiotherapy on oligo\u2010progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non\u2013small cell lung cancer patients: A longer cohort"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2163-6799","authenticated-orcid":false,"given":"Florence Siu ting","family":"Mok","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology Prince of Wales Hospital  Sha Tin Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macy","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology The Chinese University of Hong Kong  Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert H.","family":"Loong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology The Chinese University of Hong Kong  Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony S. K.","family":"Mok","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology The Chinese University of Hong Kong  Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.1315"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70184-X"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.8456"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0285"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw611"},{"issue":"10","key":"e_1_2_9_10_1","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: A database of 693 cases","author":"Yang JC","year":"2020","journal-title":"J Thorac Oncol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4921"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411817"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.3223"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182745948"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.10.012"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31827e1f83"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2233"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2013.14.8.4485"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2017.04.035"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.04.002"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-017-1723-1"},{"issue":"1","key":"e_1_2_9_22_1","first-page":"159","article-title":"Radiotherapy and tyrosine kinase inhibitors in stage IV non\u2010small cell lung cancer: Real\u2010life experience","volume":"32","author":"Borghetti P","year":"2018","journal-title":"In Vivo"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e20640"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.26494"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0349"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1118\/1.3438081"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31891"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-019-00999-w"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31829f684a"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.05.018"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2017.10.013"},{"key":"e_1_2_9_33_1","unstructured":"SchellenbergDPD.Stereotactic radiotherapy for oligo\u2010progressive metastatic cancer (The STOP Trial). NCT02756793www.clinicaltrial.gov"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.02.002"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9508"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13707","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13707","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:21:13Z","timestamp":1692649273000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/ajco.13707"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13707","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,30]]},"assertion":[{"value":"2021-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}